“Latest Stem Cells News”

Chinese researchers have become the world’s fifth most prolific contributors to peer-reviewed scientific literature on Regenerative Medicine (RM), according to an international study published on Friday (…)
Regenerative Medicine is an emerging interdisciplinary field of research and clinical applications focused on the repair, replacement or regeneration of cells, tissues, or organs, which uses a combination of approaches including gene therapy, stem cell transplantation, tissue engineering, and the reprogramming of cell and tissue types.

But as the stem cell research develops fast in recent years, RM becomes more and more dependent on this side, and shared some ethic criticism against stem cell research since it involves the usage of human embryos.

Cultured stem cells from eyes helped improve the sight of eight patients with Limbal Stem Cell Deficiency, a painful, blinding disease, British doctors said.

The patients’ own corneal cells were cultured and used to reduce corneal cloudiness from the disease, The North East England Stem Cell Institute, Newcastle, England, reported in a release Thursday.

CordLife, Asia Pacific’s largest network of stem cell banks, on Wednesday launched the most advanced umbilical cord banking technology in the country. The technology has the ability to isolate two cell types that help in hastening the healing process of diabetic foot ulcers.

The patented technology allows access epithelial stem cells that can rejuvenate skin and mucus membranes for treating non-healing wounds as is seen in diabetic ulcer patients, said Steven Fang, group CEO, CordLife. With over 4 crore people in the country diagnosed with diabetes and 1 in every 6 estimated to have an ulcer during the lifetime, CordLife expects the new umbilical cord banking technology to help harvest the right and important stem cells that may prevent amputations, Fang said.

“Typically, diabteic ulcers are very difficult to heal. With epithelial stem cells, the ulcers can be healed within 45 days,” said Meghnath Roy Chowdhury, MD, CordLife Sciences India. The company has shelled out Rs 10 crore to put in place its first cord blood storage facility near Kolkata.

from http://www.mydigitalfc.com/good-living/new-stem-cell-banking-technology-cordlife-735

CordLife, one of the leading stem cell banking groups in the Asia Pacific region, is targeting expansion of its network in India and China, considering the huge birth rate in these two Asian nations, a top official said Wednesday.
“We’re looking at India and China as two big markets in terms of our stem cell business in the Asia Pacific region – keeping in mind the huge birth rate in these two countries,” CordLife group chief executive Steven Fang told IANS Wednesday on the sidelines of a press conference here.

“We’re presently in talks with a large number of big government and private hospitals across India to tie up with them for stem cell therapy treatment.”
He said the company was growing at a rate of 70 percent in terms of its client base, and also registered 30 percent growth in its net profit last year.

Joseph Wagner sees most cell-therapy companies offering little more than a bag of cells.
His company will give the bag a little direction.

Cell Targeting is developing technology that can point stem cell therapies to specific areas of the body. Among the many challenges in cell therapy is direction: not enough of the stem cells are getting to the tissues that needs treatment (…)

Currently a stem cell therapy can help different parts of the body. That attracts more customers, but doesn’t do much when the company wants to differentiate its product and charge a different price.

A stem cell therapy tweaked by Cell Targeting can become unique because it can be directed to different areas of the body to treat different afflictions, Wagner said.

“We make them distinct by our delivery,” Wagner said. “We have the ability to make those bags of cells into unique cell-therapy products.”

Cell Targeting’s product is a peptide, a tiny piece of protein, that coats stem cells and guides them to damaged tissue. The coating peels away like paint after it gets to its target and allows the therapy to do its work (…)

But Cell Targeting’s biggest competitor may be science itself and the research underway to better understand how stem cells work. It’s likely that stem cells on their own can find their way “home” to specific tissues, Gerson said.

“We just don’t know what those Velcro connections are,” Gerson said.

Wagner said the idea that stem cells head home is a bit of “voodoo.” Only a single-digit percentage of cells return to their point of origin — and there’s no evidence they return in a larger percentage to damaged tissues, he said. Also, Wagner pointed out that in many cases, cell therapy companies don’t want stem cells to go “home” but instead to another tissue that the stem cell can also heal (…)

from http://www.medcitynews.com/index.php/2009/09/cell-targeting-ready-to-bring-purpose-to-stem-cell-therapy/

William H. Frey

Scientists have pioneered a unique delivery system to administer therapeutic stem cells to the brain, by way of a simple nasal spray. Once the droplets containing the stem cells are snorted through the nose, the solution breaks through the blood-brain barrier, seeding the brain with the stem cells (…)

Scientists from the University of Minnesota and the University Hospital of Tuebingen, Germany conducted the research. The researchers administered the nasal spray containing rat stem cells to mice and within an hour, the rat stem cells were visible in the mice brains. The researchers then repeated the experiment using human stem cells and they also penetrated the blood-brain barrier within an hour.

It’s believed the stem cells enter the brain through the olfactory nerves through small holes in the cribriform plate, which is a thin horizontal part of the skull at the base of the brain.

The researchers further found that administering an enzyme called hyaluronidase, to the mice before having them snort the stem cells, enabled greater amounts of stem cells to travel to the brain.
The nasal delivery system has obvious benefits over drilling into a patient’s skull to administer the stem cells, which can cause inflammation and infection.

Lead researcher William Frey, an adjunct professor of pharmaceutics at Minnesota noted, “When you cut into the brain, that leads to an inflammatory response,” says Frey. “We’re hoping this will help. We didn’t see evidence that intranasal stem cell treatment caused inflammation.” (…)

Scripps Research Institute scientists have offered new hope for parents whose children suffer from the rare genetic disorder ‘cystinosis’ by showing through an experiment on mice that stem cell transplantation can successfully correct the defect (…)

In the study, the researchers used bone marrow stem cell transplantation to address symptoms of cystinosis in a mouse model (…)

In the new study, the researchers found that transplanted bone marrow stem cells carrying the normal lysosomal cystine transporter gene abundantly engrafted into every tissue of the experimental mice (…)

“The results really surprised and encouraged us. Because the defect is present in every cell of the body, we did not expect a bone marrow stem cell transplant to be so widespread and effective,” says Cherqui.
Cherqui said that adult bone marrow stem cell therapy is particularly well suited as a potential treatment for cystinosis because these cells target all types of tissues.

In addition, stem cells reside in the bone marrow for the duration of a patient’’s life, becoming active as needed, a particular benefit for a progressive disease like cystinosis. The study has been published in the journal Blood.

from http://www.newkerala.com/nkfullnews-1-114380.html